NCT00073216View on ClinicalTrials.gov

Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

Not specified

Study Completion Date

September 30, 2007

Conditions
HIV Infections
Interventions
BIOLOGICAL

Clade B gag DNA/PLG and env DNA/PLG Microparticles

BIOLOGICAL

Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant

Trial Locations (4)

37232

Vanderbilt Vaccine CRS, Nashville

98104

FHCRC/UW Vaccine CRS, Seattle

Unknown

Saint Louis Univ. School of Medicine, HVTU, St Louis

02906

Miriam Hospital's HVTU, Providence

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH